InspireMD (NYSE:NSPR) Insider Shane Thomas Gleason Sells 7,186 Shares of Stock

InspireMD, Inc. (NYSE:NSPR) insider Shane Thomas Gleason sold 7,186 shares of the business’s stock in a transaction dated Friday, May 30th. The shares were sold at an average price of $2.51, for a total transaction of $18,036.86. Following the transaction, the insider directly owned 1,079,601 shares of the company’s stock, valued at $2,709,798.51. The trade was a 0.66% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Shane Thomas Gleason also recently made the following trade(s):

• On Tuesday, May 19th, Shane Thomas Gleason sold 22,778 shares of InspireMD stock. The shares were sold at an average price of $1.01, for a total transaction of $23,005.78.

InspireMD Trading Up 3.0%

Shares of NYSE:NSPR opened at $1.03 on Friday. The company has a 50 day moving average of $1.39 and a 200-day moving average of $1.67. The firm has a market cap of $48.24 million, a P/E ratio of -1.37 and a beta of 0.82. InspireMD, Inc. has a twelve month low of $0.97 and a twelve month high of $2.93.

Trending Headlines about InspireMD

Here are the key news stories impacting InspireMD this week:

• Positive Sentiment: There were no clearly positive company-specific announcements in the latest items, so investor attention is centered on the stock’s low valuation and recent trading near its 1-year low. InspireMD (NSPR) Stock Forecast & Price Target
• Neutral Sentiment: The most recent insider sale was small and attributed to tax withholding obligations tied to equity award vesting, which often makes the transactions less concerning than open-market selling. Multiple similar sales were also reported earlier this year. SEC filing
• Negative Sentiment: Repeated insider sales can still weigh on sentiment, as investors may view them as a sign of limited near-term upside or a lack of conviction from management, especially for a small-cap stock already trading below its recent moving averages. SEC filing

Institutional Trading of InspireMD

Several large investors have recently added to or reduced their stakes in NSPR. Aberdeen Group plc bought a new stake in shares of InspireMD during the 3rd quarter worth $5,979,000. Rosalind Advisors Inc. boosted its holdings in InspireMD by 70.6% in the 3rd quarter. Rosalind Advisors Inc. now owns 3,905,743 shares of the company’s stock valued at $9,413,000 after purchasing an additional 1,616,644 shares during the period. Velan Capital Investment Management LP boosted its holdings in InspireMD by 137.1% in the 3rd quarter. Velan Capital Investment Management LP now owns 2,143,698 shares of the company’s stock valued at $5,166,000 after purchasing an additional 1,239,669 shares during the period. Parkman Healthcare Partners LLC boosted its holdings in InspireMD by 97.6% in the 3rd quarter. Parkman Healthcare Partners LLC now owns 2,440,633 shares of the company’s stock valued at $5,882,000 after purchasing an additional 1,205,328 shares during the period. Finally, Nantahala Capital Management LLC boosted its holdings in InspireMD by 45.7% in the 3rd quarter. Nantahala Capital Management LLC now owns 3,376,484 shares of the company’s stock valued at $8,137,000 after purchasing an additional 1,058,467 shares during the period. 44.78% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

Several analysts recently commented on the stock. Maxim Group started coverage on shares of InspireMD in a research note on Monday, February 2nd. They set a “buy” rating and a $6.00 target price for the company. Lake Street Capital set a $4.00 price target on shares of InspireMD in a report on Monday, May 4th. Piper Sandler reiterated an “overweight” rating and issued a $3.00 price objective (down from $4.00) on shares of InspireMD in a research note on Tuesday, May 5th. Finally, Loop Capital set a $5.00 price objective on shares of InspireMD in a research note on Tuesday, February 24th. Three research analysts have rated the stock with a Buy rating, Based on data from MarketBeat, the stock currently has a consensus rating of “Buy” and an average price target of $4.50.

InspireMD Company Profile

InspireMD, Inc is a medical device company focused on developing next-generation stent technologies for cardiovascular and neurovascular interventions. The company’s core innovation lies in its MicroNet® mesh platform, a proprietary nanostructured covering designed to prevent embolic events during stent implantation. By integrating this fine mesh into traditional stent architectures, InspireMD aims to enhance safety and efficacy in the treatment of carotid artery disease and other vascular pathologies.

The company’s flagship offering, the CGuard® Embolic Prevention System (EPS), has received CE Mark approval and is commercially available in multiple international markets.